Colchicine in Coronary Artery Bypass Graft (CABG)
Study of Anti-inflammatory Treatment With Colchicine in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery to Reduce Reperfusion Damage
  • Phase

    Phase 4
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    colchicine ...
  • Study Participants

There is evidence that inflammatory processes may play a key role during surgical myocardial reperfusion. The hypothesis of this study is that colchicine, an anti-inflammatory agent, may lead to reduction in periprocedural infarct size, when administered during elective coronary artery bypass graft surgery.
Study Started
Nov 30
Primary Completion
Jun 30
Study Completion
Nov 30
Last Update
Nov 11

Drug Colchicine

colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation

Control group Placebo Comparator

Patients taking placebo

Colchicine Experimental

Active treatment group


Inclusion Criteria:

The study will enroll patients 18 years old or older who are eligible to undergo CABG surgery.

Exclusion Criteria:

Excluded are patients:

with age > 80 years old
scheduled for concomitant valve surgery
scheduled for coronary surgery without cardiopulmonary bypass
with peripheral vascular disease affecting the upper limbs
with acute coronary syndrome within the previous 4 weeks
on inotropic or mechanical circulatory support before induction of anaesthesia
with any disorder that could potentially increase preoperative cTnI concentrations (eg, percutaneous coronary intervention within the previous 6 weeks)
with active inflammatory diseases, infectious diseases or known malignancy
under treatment with corticosteroids, anti-inflammatory agents or disease modifying agents
with known hypersensitivity-allergy to colchicine
under chronic treatment with colchicine
with severe renal failure (eGFR < 35 ml/min/1.73 m2)
with hepatic failure (Child - Pugh class B or C)
No Results Posted